11月25日，A股市场震荡拉升，创业板指涨近2%。从板块来看，抗流感概念股大幅拉升，金迪克20CM 涨停，新华制药，特一药业，广济药业，海南海药，北大医药涨停，康芝药业，华兰疫苗，亨迪药业， 南新制药涨超10%，一品红，拓新药业，众生药业，粤万年青等个股跟涨。 （原标题：北京奥司他韦近7天销量暴涨237%！抗流感概念股批量涨停） （声明：文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担。） 光大证券表示，近期流感疫情上升态势明显，可能引发社会公众和市场关注度的提升，从而带动防治和 检测流感产品的需求增长。建议关注流感疫苗、病毒检测、感冒药与特效药等方面的投资机会，此外也 建议关注血制品等应对复杂态势的防疫手段。 据央广网报道，11月以来，全国流感活动快速上升，北京已迈入呼吸道传染病高发期。有数据显示，奥 司他韦近7天销量暴涨237%，速福达（玛巴洛沙韦）涨幅达180%，美团买药平台数据更显示，11月以 来北京甲乙流特效药环比增长超130%，其中速福达增长超110%，磷酸奥司他韦颗粒增长超85%。 ...

Core Insights - The flu season has arrived earlier than expected, leading to increased activity in flu-related stocks in the A-share market [1] - Significant sales increases have been reported for antiviral medications, with Oseltamivir sales up 237% and Mabalaosavir up 180% in the past week [1] Stock Performance - Notable stock movements include: - Yipinhong (一品红) up 13% - Hendi Pharmaceutical (亨迪药业) up nearly 11% - Special One Pharmaceutical (特一药业) and Guangji Pharmaceutical (广济药业) both hitting the 10% daily limit up - Other companies like Hainan Haiyao (海南海药) and Peking University Pharmaceutical (北大医药) also saw significant gains [1][2] - The overall market sentiment is positive, with many flu-related stocks experiencing substantial year-to-date increases, such as: - Yipinhong with a year-to-date increase of 225.09% - Hainan Haiyao with a 75.37% increase [2] Consumer Behavior - Data from Alibaba Health indicates a marked increase in the attention and purchase volume of flu medications over the past two weeks, with a more than 500% week-on-week growth in the number of buyers for antiviral drugs [1] - Mabalaosavir has shown exceptional performance, with a 600% increase in the number of buyers compared to the previous period, reflecting heightened consumer awareness regarding flu prevention and treatment [1]

截至2025年11月25日 11:30，中证中药指数(930641)强势上涨1.13%，成分股众生药业(002317)上涨 7.18%，粤万年青(301111)上涨6.42%，嘉应制药(002198)上涨5.49%，盘龙药业(002864)，以岭药业 (002603)等个股跟涨。中药ETF(159647)上涨1.00%，最新价报1.01元。 消息面上，上海市发文鼓励医疗机构、研发单位和药品企业共同打造中药创新与产业转化平台，鼓励中 药大品种培育和经典品种二次开发。文件指出，支持中药研发创新。建立医疗机构规范收集整理人用经 验数据机制，探索人用经验数据作为真实世界证据用于药品注册申报。制订医疗机构应用传统工艺配制 中药制剂备案管理规定。支持疗效确切、特色优势明显的医疗机构中药制剂及名老中医方开发转化为中 药新药。鼓励医疗机构、研发单位和药品企业共同打造中药创新与产业转化平台，支持中药创新药临床 研究和古代经典名方中药复方制剂研究，鼓励中药大品种培育和经典品种二次开发。外省市按照国家药 品标准生产的中药配方颗粒在我市销售的，免予备案。 数据显示，截至2025年10月31日，中证中药指数(930641)前十大权重股 ...

本公司控股股东广东金欧健康科技有限公司保证向本公司提供的信息内容 真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 1、本次公司控股股东上层股权结构变动系公司实际控制人及其一致行动人 之间的内部持股结构调整，不会导致公司控股股东、实际控制人发生变动，公司 控股股东仍为广东金欧健康科技有限公司（以下简称"金欧健康"），公司实际控 制人仍为欧先涛先生及李映华女士。本次股权结构变动尚需完成工商变更登记手 续。 2、本次股权结构变动不涉及公司层面的增持或减持行为，不会导致控股股 东、实际控制人及其一致行动人持有公司股份的数量和比例发生变化，不涉及要 约收购，不会改变公司的治理结构和管理层构成，不会对公司的日常生产经营活 动、财务状况等产生实质影响，也不存在损害公司、股东利益尤其是中小股东利 益的情形。 一、控股股东上层股权结构拟发生变动的基本情况 （一）本次股权结构变动概况 证券代码：301111 证券简称：粤万年青 公告编号：2025-058 广东万年青制药股份有限公司 关于控股股东上层股权结构拟发生变动的提示性公告 近日，公司 ...

广东万年青制药股份有限公司 简式权益变动报告书 上市公司名称：广东万年青制药股份有限公司 上市地点：深圳证券交易所 股票简称：粤万年青 信息披露义务人一：广东金欧健康科技有限公司 住所/通讯地址：汕头市龙湖区长江路 8 号 15 层 01 号房南侧 A21 信息披露义务人二（一致行动人）：汕头市奥讯有限公司 住所/通讯地址：汕头市龙湖区天山路 13 号 701-5 号房 B2 单元 信息披露义务人三（一致行动人）：欧佳煌 住所/通讯地址：广东省广州市海珠区*********** 股权变动性质：股权转让（持股数量不变，但持股人发生变化） 签署日期：2025 年 11 月 21 日 1 股票代码：301111 信息披露义务人声明 一、本报告书系信息披露义务人依据《公司法》《证券法》《上市公司收购 管理办法》《证券期货法律适用意见第 19 号—<上市公司收购管理办法>第十三 条、第十四条的适用意见》和《公开发行证券的公司信息披露内容与格式准则第 15 号-权益变动报告书》等相关法律、法规及规范性文件编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行不违反 信息披露义务人章程或内部规则中的任何条款， ...

Core Points - The company announced the transfer of 51% equity in its subsidiary Hainan Wanmitang Pharmaceutical Co., Ltd. to Guangdong He Yi Yun Kang Pharmaceutical Co., Ltd. for a price of RMB 3,373,543.10 [1] - The company has received the full payment for the equity transfer and has completed the necessary registration and documentation with the Hainan Provincial Market Supervision Administration [1] Summary by Category - **Equity Transfer** - The company approved the transfer of 51% equity in Hainan Wanmitang for RMB 3,373,543.10 [1] - The transfer has been fully paid by the acquiring party [1] - **Regulatory Compliance** - The company has completed the business registration changes and filed the updated articles of association [1] - A registration notice has been issued by the Hainan Provincial Market Supervision Administration [1]

证券代码：301111 证券简称：粤万年青 公告编号：2025-057 一、基本概况 广东万年青制药股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日召 开第三届董事会第九次会议，审议通过了《关于转让控股子公司股权的议案》， 同意公司以人民币 3,373,543.10 元的转让价格将所持有的控股子公司海南万秘 堂医药有限公司（以下简称"海南万秘堂"）51%的股权转让给广东合一云康医药 有 限 公 司 。 具 体 内 容 详 见 公 司 于 2025 年 10 月 30 日 在 巨 潮 资 讯 网 （www.cninfo.com.cn）披露的《关于转让控股子公司股权的公告》（公告编号： 2025-054）。 二、进展情况 截至本公告披露日，公司已收到受让方支付的全部股权转让价款，且海南万 秘堂已完成上述工商变更登记及《公司章程》的备案手续，并取得了海南省市场 监督管理局下发的《登记通知书》。 本次工商变更完成后，公司不再持有海南万秘堂股权，海南万秘堂不再纳入 公司合并范围。 特此公告。 广东万年青制药股份有限公司 广东万年青制药股份有限公司 关于转让控股子公司部分股权进展暨完成工商变更登记的公 ...

Core Viewpoint - The announcements from Yue Wannianqing (301111.SZ) regarding the share reduction plans by its major shareholders indicate a strategic move to liquidate holdings without affecting the company's control or governance structure [1][2]. Share Reduction Plans - The controlling shareholder, Shantou Yinkang Enterprise Management Consulting Partnership (Limited Partnership), plans to reduce its holdings by up to 1,061,520 shares, representing 0.66% of the total share capital, within three months after the announcement [1]. - Hehe Investment Holdings (Guangzhou) Partnership (Limited Partnership), holding 11,200,000 shares (7.00% of total shares), intends to reduce its holdings by up to 4,800,000 shares, or 3.00% of total shares, using both centralized bidding and block trading methods [1]. Financial Implications - Based on the closing price of 18.25 yuan on November 11, the cash amounts from the planned reductions are approximately 19.37 million yuan for Yinkang Management and 87.74 million yuan for Hehe Investment, totaling around 107 million yuan [2]. - Yinkang Management has previously reduced its holdings by 4.8 million shares, realizing approximately 82.04 million yuan in cash [2][3]. - Hehe Investment has reduced its holdings by 6.8 million shares, with total cash realized amounting to approximately 121.14 million yuan [3][4]. Shareholder Structure - The major shareholders include Guangdong Jino Health Technology Co., Ltd. (45.00%), Guangdong Qiaoyin Real Estate Development Co., Ltd. (7.50%), and Hehe Investment (7.00%) [5]. - The actual controllers of the company are Ou Xiantao and Li Yinghua, with Yinkang Management and Hehe Investment being significant stakeholders [5][6]. Financial Performance - For the first three quarters of 2025, Yue Wannianqing reported revenue of 228 million yuan, a slight decrease of 0.14% year-on-year, and a net loss attributable to shareholders of 8.13 million yuan [8][9]. - The company has experienced a decline in net profit, with a reported net profit of -812.95 thousand yuan compared to 1.41 million yuan in the same period last year [8][9].

Group 1 - Company plans to repurchase shares worth between 50 million to 100 million yuan at a price not exceeding 14.00 yuan per share to reduce registered capital [1] - Company is engaged in investment operations, environmental engineering EPC, water treatment equipment production and sales, and water environment design consulting [1] Group 2 - Company announced a change in its joint venture investment project to a "100,000 tons/year waste rubber green low-carbon recycling preparation of carbon-based new materials project" with a total investment of 88 million yuan for the first phase [2][3] Group 3 - Company received an administrative regulatory measure decision from the Beijing Securities Regulatory Commission due to the failure to timely disclose the judicial freeze of shares [4] - The controlling shareholder's shares were frozen, accounting for 13.9% of the total share capital [4] Group 4 - Company is in the product development stage for its embodied intelligent robot business, which has not yet achieved mass production or revenue generation [5][6] Group 5 - Shareholders plan to reduce their holdings by up to 2.98% of the company's total shares through various trading methods [7][8] - Company specializes in the research, design, manufacturing, and sales of material handling equipment [9] Group 6 - Shareholders plan to reduce their holdings by up to 3% of the company's total shares [10][11] Group 7 - Shareholders plan to reduce their holdings by up to 1% of the company's total shares [12][18] Group 8 - Company announced the receipt of a property with an estimated value of 133 million yuan, which is expected to increase pre-tax profits by approximately 130 million yuan for the 2025 fiscal year [17][18] Group 9 - Company announced that its main product, phosphorus trichloride, is primarily used in the production of water treatment agents [19] - The company is facing risks related to the administrative approval process for a project that is behind schedule [19] Group 10 - Controlling shareholders plan to reduce their holdings by up to 3.66% of the company's total shares [20][21] Group 11 - Company signed a strategic framework agreement with a robotics company to collaborate on applications in intelligent manufacturing [22] Group 12 - Company plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [23] Group 13 - Controlling shareholder plans to transfer 5% of the company's shares as part of a cash acquisition arrangement [24] Group 14 - Company announced a change in control with a new controlling party following a share transfer agreement [25] Group 15 - Company plans to transfer 60% of its subsidiary's equity at a base price of 1.6756 million yuan, which is expected to reduce net profit by approximately 26.4 million yuan for the 2025 fiscal year [26] Group 16 - Major shareholder plans to provide a loan of up to 1.666 billion yuan to the company for debt repayment purposes [27]

Group 1 - The core viewpoint of the news is that Guangdong Wannianqing Pharmaceutical Co., Ltd. has shown significant trading activity and financial performance indicators, with a notable increase in financing buy-ins and a decrease in shareholder numbers [1][2]. Group 2 - On November 11, Guangdong Wannianqing's stock rose by 2.53%, with a trading volume of 104 million yuan. The financing buy-in amount for the day was 13.32 million yuan, while the financing repayment was 7.94 million yuan, resulting in a net financing buy-in of 5.37 million yuan [1]. - As of November 11, the total financing and securities lending balance for Guangdong Wannianqing was 64.80 million yuan, which accounts for 2.22% of its market capitalization. This financing balance is above the 70th percentile level over the past year, indicating a relatively high position [1]. - The company has not engaged in securities lending activities on November 11, with no shares sold or repaid, and the securities lending balance remains at zero, placing it in the 90th percentile level over the past year [1]. Group 3 - As of September 30, the number of shareholders for Guangdong Wannianqing was 11,400, a decrease of 7.18% from the previous period. The average circulating shares per person increased by 7.74% to 13,994 shares [2]. - For the period from January to September 2025, Guangdong Wannianqing reported operating revenue of 22.8 million yuan, a slight decrease of 0.14% year-on-year. The net profit attributable to the parent company was -8.13 million yuan, representing a significant decline of 157.65% year-on-year [2]. - Since its A-share listing, Guangdong Wannianqing has distributed a total of 65.60 million yuan in dividends, with 40 million yuan distributed over the past three years [2].